Skip to Main Content
Yale School of Medicine
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Wajih Kidwai, MD, FACP

Associate Professor of Medicine (Medical Oncology); Medical Director, Smilow Cancer Hospital in Guilford

Contact Information

Wajih Kidwai, MD, FACP
Download CV
Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

I have had the honor and responsibility of working as the Medical Director of our office in Guilford and have maintained my position as it transitioned to Yale Smilow Guilford in 2012. As a result of great patient care development, quality of care and provision of state of the art cancer care here we have been able to expand our services with increased surgical and radiology services and by opening another office in Old Saybrook.

I work in collaboration with Radiation Oncology, which provides excellent service to the patients in our shoreline facility. We have worked together with Radiation Oncology on development of a busy Breast Cancer program with Radiation Oncology, breast surgery and breast radiology.

We have worked together on a number of studies here and are part of Clinical Research Working Group (CRWG) bringing research to the Smilow care centers.

I also attend and contribute to the Institutional Review Board (IRB) for Oncology protocols and have been actively participating since 2012. Having a very busy clinical practice, I usually use the weekend and off-hours to prepare for theses meetings and protocols. I have placed a number of patients on practice changing clinical trials resulting in presentations, papers and abstracts.

I am also honored to represent Yale University/Smilow Cancer Center in the hematopoietic panel of NCCN. I previously was also on the NCCN Panel of Neuroendocrine Tumors.

I have taken an active part in the Yale Quality program and in association with Dr. Anne Chiang and Dr. Kerin Adelson. In November of 2018 I presented our Goals of Care quality project at American Society of Clinical Oncology Palliative Care symposium in San Diego, CA.

I am also working closely with the Survivorship program and Breast cancer related Nutrition and Exercise related trials under the direction of Dr Tara Sanft.

We also are collaborating with Smoking cessation program and Yale palliative care program at the care center.

Extensive Research Description

Clinical trials.... see attached data of Clinical trial/ Investigator/ sub investigator

Clinical Research Working group

IRB oncology Yale University

Coauthors

Research Interests

Breast Neoplasms; Colonic Neoplasms; Lung Neoplasms; Lymphoma; Pancreatic Neoplasms

Selected Publications

Clinical Trials

ConditionsStudy Title
LungRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
BreastAn Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
LungA Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Non-Hodgkin's LymphomaA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
Multiple MyelomaNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
PancreasA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
ProstateSIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
Multiple MyelomaEffective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
BreastA Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
LungIntegration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
LungMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Other Female Genital; OvaryA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
LungPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Corpus UteriA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
Multiple MyelomaDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Esophagus; Larynx; Lip, Oral Cavity and PharynxA Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
LungLUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Leukemia, not otherwise specified; Leukemia, otherPhase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
BreastRandomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Other Urinary; Urinary BladderPhase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Edit Profile